Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD40 | P25942 | 2/20 | 0.49 |
| ▸ | CD40LG | P29965 | 2/20 | 0.49 |
| ▸ | CCR8 | P51685 | 4/20 | 0.48 |
| ▸ | TIMP3 | P35625 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6242899 | 0.91 | CCR8 (0.58) | CD40CD40LGCCR8TIMP3RAB9A | |
| SCHEMBL1339026 | 0.89 | NPC1 (0.62) | CD40CD40LGCCR8RAB9ANPC1 | |
| SCHEMBL10902168 | 0.83 | TTR (0.53) | CD40CD40LGRAB9ACYP1A2TTR | |
| SCHEMBL6241585 | 0.83 | TIMP3 (0.56) | TIMP3RAB9ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1338412 | 0.81 | CCR8 (0.70) | CD40CD40LGCCR8TIMP3RAB9A | |
| SCHEMBL6073527 | 0.81 | CASP6 (0.60) | CYP1A2TTRMEN1KMT2AALDH1A1 | |
| SCHEMBL6242038 | 0.80 | CD40 (0.61) | CD40CD40LGTIMP3RAB9ANPC1 | |
| SCHEMBL4108482 | 0.80 | CCR8 (0.68) | CD40CD40LGCCR8TIMP3RAB9A | |
| SCHEMBL11782093 | 0.79 | HSD17B10 (0.56) | CD40CD40LGCCR8TIMP3RAB9A | |
| SCHEMBL21912407 | 0.78 | PARP1 (0.41) | CD40CD40LGCCR8TIMP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315695-B1 | BENZENE TRICARBOXYLIC ACID AMIDES AS INSULIN RECEPTOR ACTIVATORS | TELIK INC (US) | 2005-07-13 | — | — | EP | claimed |
| US-6600069-B2 | Insulin receptor kinase activators; treating hyperglycemia; 4-((3,5-bis(N-(4-sulfophenyl)carbamoyl)phenyl)carbonylamino)-benzenesulfonic acid, for example | TELIK, INC. | 2003-07-29 | — | — | US | claimed |
| US-20020103183-A1 | Benzene tricarboxylic acid derivatives as insulin receptor activators | TELIK, INC. | 2002-08-01 | — | — | US | claimed |
| EP-1315695-B1 | BENZENE TRICARBOXYLIC ACID AMIDES AS INSULIN RECEPTOR ACTIVATORS | TELIK INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6600069-B2 | Insulin receptor kinase activators; treating hyperglycemia; 4-((3,5-bis(N-(4-sulfophenyl)carbamoyl)phenyl)carbonylamino)-benzenesulfonic acid, for example | TELIK, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20020103183-A1 | Benzene tricarboxylic acid derivatives as insulin receptor activators | TELIK, INC. | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103183-A1 | Benzene tricarboxylic acid derivatives as insulin receptor activators | GPR119, INSR, IRS1 | CD40 1424/4885CD40LG 2403/4885CCR8 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.